How to access Exondys 51 from Saudi Arabia — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Saudi family of a boy with Duchenne muscular dystrophy (DMD) whose genotyping confirms an exon-51-skip-amenable mutation may receive a prescription for Exondys 51 (eteplirsen) from their treating paediatric neurologist. Exondys 51 is FDA-approved, manufactured by Sarepta Therapeutics, and is an antisense oligonucleotide that restores partial dystrophin production in patients whose DMD mutation is amenable to exon 51 skipping — roughly 13% of the DMD population. In Saudi Arabia, Exondys 51 is not locally registered for routine dispensing, which is why your paediatric neurologist is likely guiding you toward the Saudi Food and Drug Authority (SFDA) named-patient import pathway.

This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Exondys 51 is a phosphorodiamidate morpholino oligomer (PMO) administered by weekly intravenous infusion, indefinitely. Eligibility is strictly genotype-gated: your child's DMD gene mutation must be confirmed by accredited genetic testing as amenable to exon 51 skipping. Treatment requires a paediatric neurologist with DMD experience, a day-infusion facility, and ongoing monitoring including renal function, cardiac assessment, and motor-function scales (NSAA, 6MWT). Dosing is weight-based and is given in perpetuity; this is a long-term commitment rather than a finite course.

Is Exondys 51 legally importable into Saudi Arabia?

Yes — through the SFDA named-patient import framework, administered in coordination with the Ministry of Health for patients treated in public tertiary centres.

The named-patient mechanism allows a Saudi-licensed physician to request import of a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is available, (c) the physician takes clinical responsibility, and (d) the importing party documents the chain of custody end to end. For exon-51-amenable DMD in Saudi Arabia, there is no locally registered exon-skipping alternative, making the clinical rationale straightforward once genotype is confirmed.

How the pathway works, step by step

1. Consultation with your paediatric neurologist. Confirmation of DMD diagnosis and exon-51-skip-amenable genotype, with baseline NSAA, 6MWT, cardiac, and renal assessments documented.
2. Treatment-centre identification. A tertiary hospital with paediatric neurology and infusion-day-unit capacity is confirmed as the administering site.
3. SFDA named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, genotyping report, patient reference, and chain-of-custody plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Exondys 51 from Sarepta's authorised distribution channel.
5. Shipment. The product ships under chain-of-custody and manufacturer handling conditions to the administering hospital pharmacy.
6. Arrival and first infusion. The treating hospital administers the weekly infusion and establishes the ongoing schedule; Reserve Meds coordinates rolling refills.

What documentation your physician needs

Your physician will typically need to provide:

• A clinical rationale letter confirming DMD diagnosis, exon-51-skip-amenable mutation, baseline motor and cardiac status, and Exondys 51 as the indicated treatment
• Verification of their Saudi medical licence (SCFHS / MOH)
• A copy of the accredited DMD genetic-testing report
• Patient identifier (anonymised reference where possible)
• An administration and monitoring plan including weekly infusion scheduling and long-term follow-up

Reserve Meds provides a physician documentation kit with the templates SFDA reviewers expect to see for rare-paediatric-neurology named-patient imports, including the exon-skipping genotype gate that is central to Exondys 51 eligibility.

Costs and timing

Exondys 51 is weight-dependent in dosing, so annual cost scales with the child's body weight. Indicative 2026 US cash-pay annual cost for Exondys 51 sits in a broad range of roughly USD 300,000 to over USD 1,000,000 depending on weight, with adolescents and older children at the upper end. International logistics, SFDA documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.

Indicative timing — not guaranteed — for the first infusion after cohort intake opens is approximately 14–28 days from the moment a complete SFDA application is submitted. Subsequent weekly supply runs on a rolling refill schedule once the pathway is established.

Reserve Meds is in pre-launch. Fulfilment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: DMD clusters in families with shared ancestry, and in Saudi Arabia consanguineous marriage patterns mean multiple affected boys in one extended family are not uncommon. Our concierge coordination is designed around the extended-family caregiving pattern — an uncle, aunt, or grandparent can be a designated case contact, and we coordinate refill logistics around school schedules and family travel between the Kingdom, the Gulf, and Europe.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Exondys 51 specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and for SFDA review, tailored to exon-skipping eligibility.
• Logistics. Chain-of-custody shipment coordination to the administering hospital pharmacy on a weekly-refill cadence.
• Concierge case lead. A named point of contact for the family, managing long-term refill logistics and weight-based dose adjustments as the child grows.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating paediatric neurologist. We operate on a waitlist basis during our pre-launch phase.

Frequently asked

Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation. Cross-border named-patient import for rare-paediatric-disease therapies is a recognised mechanism. See our trust and compliance page.

Is Exondys 51 a cure? No. Exondys 51 is a disease-modifying therapy that restores partial dystrophin expression in exon-51-amenable DMD patients. Your paediatric neurologist will discuss realistic outcome expectations and long-term monitoring.

What if my son's mutation is not exon-51-amenable? Exondys 51 is genotype-specific. Other exon-skipping therapies target exons 45, 53, and others; if your son's mutation is amenable to a different exon skip, that product would be the relevant candidate. Your neurologist's genotype report guides the choice.

Does the infusion have to happen in a hospital? Weekly IV infusion requires an infusion-day unit with paediatric expertise. Home infusion is not currently standard for Exondys 51 in Saudi Arabia.

Will insurance or MoH coverage apply? Cash-pay is the default. Some Saudi patients may receive partial MoH coverage or private-insurance consideration on a case-by-case basis; we supply documentation for submission but do not process public-payer or insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Exondys 51 coordination in Saudi Arabia.

Add me to the Exondys 51 waitlist

---

Composite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.